Evofem Biosciences (EVFM) Competitors $0.0091 0.00 (-6.19%) As of 08/22/2025 03:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. SLXN, DRMA, INDP, EVAX, JAGX, TCRT, NBY, GRI, VRAX, and RDHLShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Silexion Therapeutics (SLXN), Dermata Therapeutics (DRMA), Indaptus Therapeutics (INDP), Evaxion A/S (EVAX), Jaguar Animal Health (JAGX), Alaunos Therapeutics (TCRT), NovaBay Pharmaceuticals (NBY), GRI Bio (GRI), Virax Biolabs Group (VRAX), and Redhill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Silexion Therapeutics Dermata Therapeutics Indaptus Therapeutics Evaxion A/S Jaguar Animal Health Alaunos Therapeutics NovaBay Pharmaceuticals GRI Bio Virax Biolabs Group Redhill Biopharma Silexion Therapeutics (NASDAQ:SLXN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Do insiders and institutionals believe in SLXN or EVFM? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, SLXN or EVFM? Silexion Therapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Which has higher earnings & valuation, SLXN or EVFM? Evofem Biosciences has higher revenue and earnings than Silexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/AEvofem Biosciences$11.39M0.09$52.98M-$0.07-0.13 Do analysts prefer SLXN or EVFM? Silexion Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 944.57%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Silexion Therapeutics is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SLXN or EVFM more profitable? Silexion Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Silexion Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% Evofem Biosciences -46.42%-91.97%-61.93% Does the media refer more to SLXN or EVFM? In the previous week, Evofem Biosciences had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 3 mentions for Evofem Biosciences and 2 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.67 beat Evofem Biosciences' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySilexion Therapeutics beats Evofem Biosciences on 9 of the 13 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08M$834.78M$5.75B$9.62BDividend YieldN/A4.84%4.40%4.10%P/E Ratio-0.011.1831.2526.05Price / Sales0.0926.35433.91193.97Price / CashN/A19.5637.7358.48Price / Book0.006.649.536.61Net Income$52.98M-$4.94M$3.26B$265.65M7 Day PerformanceN/A1.85%2.13%2.03%1 Month PerformanceN/A2.72%2.80%-0.31%1 Year PerformanceN/A10.97%30.68%19.06% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences1.3147 of 5 stars$0.01-6.2%N/A-6.2%$1.08M$11.39M-0.01120News CoverageSLXNSilexion Therapeutics1.5343 of 5 stars$7.48+3.3%$75.00+902.7%N/A$4.20MN/A0.00N/ANews CoverageDRMADermata Therapeutics2.7344 of 5 stars$5.81-2.8%$30.00+416.4%-70.2%$4.08MN/A-0.358Positive NewsAnalyst ForecastINDPIndaptus Therapeutics2.6519 of 5 stars$7.76+9.0%$238.00+2,967.0%-83.5%$4.08MN/A-0.216EVAXEvaxion A/S2.4985 of 5 stars$3.22+11.8%$10.00+210.6%-79.2%$4.04M$3.34M-2.4460Gap UpHigh Trading VolumeJAGXJaguar Animal Health2.2386 of 5 stars$2.07-1.4%$60.00+2,798.6%-94.1%$4.02M$11.81M0.0050News CoverageTCRTAlaunos Therapeutics1.1106 of 5 stars$2.33+3.6%N/A-35.2%$3.69M$10K-0.9540News CoveragePositive NewsNBYNovaBay Pharmaceuticals0.3694 of 5 stars$0.62+0.9%$0.85+36.5%+80.6%$3.62M$9.78M-0.0130Gap DownGRIGRI Bio1.7199 of 5 stars$1.47+5.8%$22.00+1,396.6%-83.5%$3.50MN/A-0.131News CoverageShort Interest ↑VRAXVirax Biolabs Group3.2111 of 5 stars$0.78+1.1%$3.00+283.0%-85.2%$3.36M$10K0.005Positive NewsShort Interest ↓Gap DownRDHLRedhill BiopharmaN/A$1.44+5.9%N/A-86.3%$3.12M$8.04M0.00210Gap Up Related Companies and Tools Related Companies Silexion Therapeutics Alternatives Dermata Therapeutics Alternatives Indaptus Therapeutics Alternatives Evaxion A/S Alternatives Jaguar Animal Health Alternatives Alaunos Therapeutics Alternatives NovaBay Pharmaceuticals Alternatives GRI Bio Alternatives Virax Biolabs Group Alternatives Redhill Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access